3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
3
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Squamous Cell Carcinoma of Head and Neck
8
Head and Neck Neoplasms
6
Breast Neoplasms
5
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Pancreatic Neoplasms
3
Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Uterine Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms by Site
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
4
pembrolizumab
3
selpercatinib
2
pralsetinib
2
Pemetrexed
2
Paclitaxel
2
Fulvestrant
2
Carboplatin
2
trametinib
1
ribociclib
1
repotrectinib
1
patritumab
1
palbociclib
1
golotimod
1
exemestane
1
dabrafenib
1
cobimetinib
1
alectinib
1
abemaciclib
1
Vemurafenib
1
Taxes
1
Tamoxifen
1
STX-478
1
Radiotherapy, Intensity-Modulated
1
Nimorazole
1
Metformin
1
Letrozole
1
Imlunestrant
1
Gemcitabine
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
palbociclib
×
Head & Neck
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled